Kexing hepatitis A vaccine exclusively wins a two-year contract in Oman.

On January 22nd, according to information from Sinovac Biotech, Sinovac's inactivated hepatitis A vaccine, HAVRIX, has exclusively won the bid for the public market project in Oman for the years 2026-2027. Up to now, Sinovac's hepatitis A vaccine HAVRIX has supplied over 130 million doses to nearly 50 countries and regions worldwide.